Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 30, 2022 (4 years ago)

Neostigmine Methylsulfate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Neostigmine Methylsulfate Injection, USP, 4 mg/4 mL (1 mg/mL) syringe, packaged in 5 x 4 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-942-04

Affected NDC 69374-0942-04

Compare with the code on your package — it is the most precise check available.

Drug: Neostigmine

Recalling firm
Nephron Sterile Compounding Center LLC
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1271-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Neostigmine recalls

See all
Class II · Moderate risk

neostigmine 5 mg/5mL

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-0982-2023

Other recalls by Nephron Sterile Compounding Center LLC

All 2022 recalls